Kintor Pharma Announces Dosing Of First Patient In Phase II Clinical Trial Of KX-826 For The Treatment Of Androgenic Alopecia Female Patients In China

Publish date:

SUZHOU, China, Nov. 12, 2021/ PRNewswire/– Kintor Pharmaceutical Limited (” Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology business establishing ingenious little particle and biological rehabs, today revealed that the business has actually dosed …

SUZHOU, China, Nov. 12, 2021/ PRNewswire/– Kintor Pharmaceutical Limited (” Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology business establishing ingenious little particle and biological rehabs, today revealed that the business has actually dosed the very first client in its stage II medical trial of pyrilutamide (” KX-826″) in China for the treatment of androgenetic alopecia (AGA) female clients.

The stage II trial is a randomized, double-blind, placebo-controlled, multi-regional research study to examine the effectiveness and security of KX-826 for the treatment of AGA in adult women (N =-LRB- ). The main endpoint for the trial is the modification from standard in non-vellus target location hair counts (TAHC) at week24

.

Dr. Youzhi Tong, creator, Chairman and CEO of Kintor Pharma, commented, “The population of those who struggle with loss of hair has a great deal and tends to be more youthful. By the end of 2020, the variety of loss of hair in China had actually surpassed 252 million, amongst which about 87 million were ladies. AGA represents around 90%of clients with loss of hair, however there are couple of healing drugs. A more secure and more reliable drug is in immediate requirement to deal with the issues for the individuals suffering from hair loss. As a topical AR villain with a determined target, KX-826 has actually revealed excellent effectiveness and security profile in the stage II scientific trial in China for the treatment of AGA male clients. We eagerly anticipate additional broadening the scientific capacity of KX-826 and benefiting more individuals struggling with loss of hair.”

About KX-826

.

KX-826 is an androgen receptor (AR) villain and a prospective first-in-class topical drug for the treatment of AGA and acne vulgaris. For the AGA indicator, on 8 September 2021, Kintor Pharma revealed that the main endpoint of the stage II medical trial of KX-826 on adult male clients was satisfied, as outcomes revealed excellent effectiveness and security profile. On 11 July 2021, Kintor Pharma revealed that the Food and Drug Administration of the United States greenlighted KX-826’s stage II scientific trial for AGA to be carried out in the United States For the acne vulgaris sign, the stage I medical trial of KX-826 for the treatment of acne vulgaris has actually been finished, and Kintor Pharma is getting ready for stage II medical trial in China

About Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited is establishing and advertising a robust pipeline of ingenious little particle and biological rehabs for androgen-receptor-related illness locations with unmet medical requirements, consisting of COVID-19, prostate, breast and liver cancer, alopecia, and acne. For more details, go to www.kintor.com.cn

Contact Information

IR Team IR@kintor.com.cn

.

PR Team PR@kintor.com.cn

.

View initial material: https://www.prnewswire.com/news-releases/kintor-pharma-announces-dosing-of-first-patient-in-phase-ii-clinical-trial-of-kx-826- for-the-treatment-of-androgenic-alopecia-female-patients-in-china-301422829 html

.

SOURCE Kintor Pharma

Read More

Author: admin

Leave a Reply

Your email address will not be published. Required fields are marked *